A review published in the New England Journal of Medicine sets out the latest advances in multiple sclerosis treatment, highlighting progress in drug therapies for relapsing disease while calling for better options to stop progression and repair nerve damage.
—
What the Review Found
The New England Journal of Medicine has published a major review of multiple sclerosis treatment, summarising where medicine now stands — and where it still falls short.
At the same time, the review focuses on disease-modifying therapies for relapsing MS, the most common form of the condition. These are drugs designed to reduce the frequency and severity of relapses, when symptoms flare up and then partially or fully ease.
But the review doesn’t stop at what’s working. It points directly to two areas where progress is still needed: treatments that can prevent long-term disability progression, and therapies that might rebuild myelin — the protective sheath around nerve fibres that MS gradually destroys.
Why Myelin Matters
Myelin loss is at the heart of MS. When it breaks down, nerve signals slow or stop altogether, causing the wide range of symptoms MS patients live with — from fatigue and muscle weakness to problems with vision, balance, and memory.
Current treatments can slow the attack on myelin in relapsing disease. Repairing it is a different challenge entirely, and one the review identifies as a gap that medicine hasn’t yet closed.
The New England Journal of Medicine is one of the world’s most widely read and cited medical journals. A review article of this kind pulls together evidence from multiple studies to give clinicians a clear picture of where the field stands.
Relapsing MS Versus Progressive MS
MS takes several forms. Relapsing-remitting MS — where symptoms come and go — affects the majority of people diagnosed with the condition. Disease-modifying therapies have advanced considerably for this group over the past two decades.
Progressive MS, where disability worsens steadily without clear relapses, is harder to treat. The review underlines that this remains an area of unmet need. Patients with progressive forms of the condition have fewer effective options available to them.
The Bigger Picture
Around 130,000 people in the UK are living with MS, according to the MS Society. It’s most commonly diagnosed in people in their twenties and thirties, and affects more women than men.
Treatment has moved on considerably since the first disease-modifying drugs were licensed in the 1990s. Yet for many patients — especially those with progressive disease — the options remain limited compared to those with relapsing forms.
The NEJM review signals that remyelination, the process of rebuilding myelin, is now a recognised target for the next generation of MS treatments. Clinical trials in this area are ongoing, though no remyelinating therapy has yet been approved for routine use.
—
Source: @NEJM
Key Takeaways
- A New England Journal of Medicine review summarises current advances in MS treatment, with a focus on disease-modifying therapies for relapsing disease
- The review identifies two gaps: better treatments to prevent disability progression, and therapies that can rebuild myelin — the nerve-protecting sheath damaged by MS
- Around 130,000 people in the UK live with MS, and while relapsing disease treatment has improved, progressive MS remains harder to manage
—
What This Means for Kent Residents
Around 130,000 people across the UK are living with MS — meaning thousands of families in Kent are affected, whether as patients, carers, or both. If you or someone you know has been diagnosed with MS, your GP or NHS neurologist is the right first point of contact for questions about disease-modifying therapies and what the latest evidence means for your care. The MS Society helpline — reachable on 0808 800 8000 — offers free, confidential support and can help you understand your treatment options and connect you with local support groups across Kent. For urgent health concerns, contact NHS 111, or call 999 in an emergency.